COST-EFFECTIVENESS OF A FIXED DOSE COMBINATION OF ALENDRONATE AND CHOLECALCIFEROL IN THE TREATMENT OF WOMEN WITH OSTEOPOROSIS AT RISK FOR VITAMIN D DEFICIENCY

被引：0
|
作者：
Ghosh, Sabyasachi [1 ]
Fan, Tao [2 ]
Modi, Ankita [2 ]
Jansen, Jeroen [1 ]
Sen, Shuvayu [2 ]
机构：
[1] MapiValues, Clin & Econ Evidence, Boston, MA USA
[2] Merck & Co Inc, Global Hlth Outcomes, Whitehouse Stn, NJ USA
来源：
OSTEOPOROSIS INTERNATIONAL | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：132 / 133
页数：2
相关论文
共 50 条
  • [41] Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
    E. Söreskog
    I. Lindberg
    J.A. Kanis
    K.E. Åkesson
    D. Willems
    M. Lorentzon
    O. Ström
    P. Berling
    F. Borgström
    Osteoporosis International, 2021, 32 : 585 - 594
  • [42] Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
    Soreskog, E.
    Lindberg, I.
    Kanis, J. A.
    Akesson, K. E.
    Willems, D.
    Lorentzon, M.
    Strom, O.
    Berling, P.
    Borgstrom, F.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (03) : 585 - 594
  • [43] Cost-effectiveness of parathyroid hormone in the treatment of osteoporosis in postmenopausal women in the UK
    Lundkvist, J
    Jonssson, L
    Johnell, O
    Sykes, D
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S11 - S11
  • [44] Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women
    J. A. Kanis
    F. Borgstrom
    O. Johnell
    B. Jonsson
    Osteoporosis International, 2004, 15 : 862 - 871
  • [45] Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women
    Kanis, JA
    Borgstrom, F
    Johnell, O
    Jonsson, B
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 (11) : 862 - 871
  • [46] The cost-effectiveness of parathyroid hormone and alendronate in high-risk osteoporotic women.
    Liu, H
    Michaud, K
    Nayak, S
    Karpf, DB
    Owens, DK
    Garber, AM
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S409 - S409
  • [47] The cost-effectiveness of risendronate compared to alendronate in post-menopausal women with established osteoporosis: A Polish analysis
    Orlewska, E
    Lis, J
    Gierczynski, J
    VALUE IN HEALTH, 2005, 8 (06) : A136 - A136
  • [48] COST-EFFECTIVENESS OF ALENDRONATE THERAPY FORCORTICOSTEROID-INDUCED OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS IN JAPAN
    Moriwaki, K.
    Noto, S.
    Inoue, H.
    Yanagisawa, S.
    VALUE IN HEALTH, 2012, 15 (07) : A447 - A447
  • [49] The cost-effectiveness of parathyroid hormone and alendronate in high-risk osteoporotic women.
    Michaud, K
    Liu, H
    Nayak, S
    Owens, DK
    Garber, AM
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S266 - S266
  • [50] The cost-effectiveness of bisphosphonates, raloxifene and hormone replacement therapy in women with established osteoporosis and replete of calcium and vitamin D
    Stevenson, MD
    Brazier, JE
    Lloyd-Jones, M
    Calvert, N
    Oakley, J
    Kanis, JA
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 : S111 - S111
12345